NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One-Shot gene therapy could free wet AMD patients from monthly eye needles
Disease control Recruiting nowThis study tests a single injection of LX102 gene therapy under the retina for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can maintain or improve vision better than standard anti-VEGF injections, potentially re…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 08:01 UTC
-
One shot to save sight? gene therapy trial aims to cut eye injections for wet AMD
Disease control Recruiting nowThis phase 3 trial tests a single injection of 4D-150 gene therapy in 480 adults with wet age-related macular degeneration (nAMD). The goal is to see if one treatment can control the disease and reduce the need for regular eye injections over two years. Participants must be 50 or…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
One-Shot gene therapy could replace monthly eye injections for wet AMD
Disease control Recruiting nowThis Phase 3 trial tests a single injection of Ixo-vec gene therapy in 284 people with wet age-related macular degeneration (nAMD). The goal is to see if it can maintain or improve vision as well as standard aflibercept injections, but with fewer treatments needed. Participants r…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC